AnaptysBio, Inc. to Post Q3 2024 Earnings of ($1.62) Per Share, Wedbush Forecasts (NASDAQ:ANAB)

AnaptysBio, Inc. (NASDAQ:ANAB) – Wedbush boosted their Q3 2024 earnings per share estimates for shares of AnaptysBio in a report released on Monday, August 5th. Wedbush analyst D. Nierengarten now anticipates that the biotechnology company will earn ($1.62) per share for the quarter, up from their previous estimate of ($1.71). Wedbush currently has a “Outperform” rating and a $34.00 target price on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($6.32) per share. Wedbush also issued estimates for AnaptysBio’s Q4 2024 earnings at ($1.68) EPS, FY2024 earnings at ($6.65) EPS, Q1 2025 earnings at ($1.46) EPS, Q2 2025 earnings at ($1.49) EPS, Q3 2025 earnings at ($1.52) EPS, Q4 2025 earnings at ($1.55) EPS, FY2025 earnings at ($6.03) EPS, FY2026 earnings at ($6.12) EPS, FY2027 earnings at ($6.43) EPS and FY2028 earnings at ($7.05) EPS.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Monday, August 5th. The biotechnology company reported ($1.71) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.82). The business had revenue of $10.97 million for the quarter, compared to analysts’ expectations of $25.85 million. AnaptysBio had a negative net margin of 711.17% and a negative return on equity of 161.40%.

Several other equities research analysts have also issued reports on the company. HC Wainwright reissued a “buy” rating and set a $55.00 price target on shares of AnaptysBio in a research report on Tuesday. SVB Leerink started coverage on AnaptysBio in a research report on Tuesday, April 16th. They issued an “outperform” rating and a $47.00 target price on the stock. JPMorgan Chase & Co. increased their target price on AnaptysBio from $69.00 to $75.00 and gave the stock an “overweight” rating in a research report on Wednesday. Finally, Leerink Partnrs reaffirmed an “outperform” rating on shares of AnaptysBio in a research report on Tuesday, April 16th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $52.56.

AnaptysBio Price Performance

Shares of ANAB stock traded down $0.54 on Thursday, hitting $33.05. 172,526 shares of the stock traded hands, compared to its average volume of 327,084. The company has a market capitalization of $902.89 million, a PE ratio of -5.38 and a beta of -0.25. AnaptysBio has a 1-year low of $13.36 and a 1-year high of $38.85. The company’s fifty day moving average is $28.39 and its 200 day moving average is $25.21.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC acquired a new position in shares of AnaptysBio in the 1st quarter valued at $38,000. Headlands Technologies LLC boosted its position in shares of AnaptysBio by 444.8% in the 2nd quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock valued at $89,000 after purchasing an additional 2,900 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in shares of AnaptysBio by 66.8% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 5,123 shares of the biotechnology company’s stock valued at $115,000 after purchasing an additional 2,051 shares during the period. Quest Partners LLC acquired a new position in shares of AnaptysBio in the 4th quarter valued at $119,000. Finally, SG Americas Securities LLC acquired a new position in shares of AnaptysBio in the 4th quarter valued at $126,000.

Insider Activity

In other news, CFO Dennis Mulroy sold 1,500 shares of the firm’s stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $23.72, for a total transaction of $35,580.00. Following the transaction, the chief financial officer now directly owns 964 shares of the company’s stock, valued at $22,866.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CFO Dennis Mulroy sold 1,500 shares of the firm’s stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $23.72, for a total transaction of $35,580.00. Following the completion of the transaction, the chief financial officer now owns 964 shares of the company’s stock, valued at $22,866.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Hollings Renton sold 10,000 shares of the firm’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $30.64, for a total value of $306,400.00. Following the transaction, the director now directly owns 1,950 shares of the company’s stock, valued at approximately $59,748. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 16,900 shares of company stock valued at $484,824. Company insiders own 33.70% of the company’s stock.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.